With 10 mobile community research sites in the US, the move expands the organization’s international reach.
EmVenio Research, in collaboration with UK-based EMS Healthcare, will establish and operate commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales, and Scotland. Each of the sites will be supported by a dedicated local workforce. EmVenio will be responsible for full clinical oversight, with principal and sub-investigators, and team leaders, and will oversee clinical trial operations and data management.
EmVenio currently operates research in 10 mobile community research sites across the United States.
Keith Austin, CEO of EMS Healthcare, said in press release, "A recent independent review of commercial clinical trials by Lord James O'Shaughnessy acknowledged the crucial role of mobile clinics in delivering trials with more diverse participation. We believe this initiative will attract more pharmaceutical sponsors to carry out trials, which will have a significant impact on both the U.K. economy and the health of our population."
Reference: EmVenio Research expands internationally with 10 research sites in the UK. DURHAM, N.C., June 20, 2023 /PRNewswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.